Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.

被引：9
|
作者：
Varghese, Anna M.
Patel, Juber Ahamad A.
Janjigian, Yelena Yuriy
Meng, Fanli
Selcuklu, S. Duygu
Zimel, Catherine
Hyman, David Michael
Iyer, Gopa
Houck-Loomis, Brian
Abou-Alfa, Ghassan K.
Berger, Michael F.
Lowery, Maeve Aine
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA
[4] Trinity Coll Dublin, Dublin, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.4096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4096
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
    Varghese, Anna M.
    Patel, Juber
    Janjigian, Yelena Y.
    Meng, Fanli
    Selcuklu, S. Duygu
    Iyer, Gopakumar
    Houck-Loomis, Brian
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    Lowery, Maeve A.
    Berger, Michael F.
    JCO PRECISION ONCOLOGY, 2021, 5 : 44 - 50
  • [2] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Vu, Phuong
    Deshpande, Vikram
    Kambadakone, Avinash
    Mussolin, Benedetta
    Reyes, Stephanie
    Henderson, Laura
    Sun, Jiaoyuan Elisabeth
    Van Seventer, Emily E.
    Gurski, Joseph M., Jr.
    Baltschukat, Sabrina
    Schacher-Engstler, Barbara
    Barys, Louise
    Stamm, Christelle
    Furet, Pascal
    Ryan, David P.
    Stone, James R.
    Iafrate, A. John
    Getz, Gad
    Porta, Diana Graus
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER DISCOVERY, 2017, 7 (03) : 252 - 263
  • [3] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Phuong Vu
    Mussolin, Benedetta
    Reyes, Stephanie
    Furet, Pascal
    Iafrate, A. John
    Getz, Gad
    Porta, Diana G.
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER RESEARCH, 2017, 77
  • [4] Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.
    Boileve, Alice
    Baiev, Islam
    Dinicola, Caroline
    Horick, Nora K.
    Tazdait, Melodie
    Zhu, Andrew X.
    Hollebecque, Antoine
    Goyal, Lipika
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] FGFR2 Inhibition in Cholangiocarcinoma
    Vogel, Arndt
    Segatto, Oreste
    Stenzinger, Albrecht
    Saborowski, Anna
    ANNUAL REVIEW OF MEDICINE, 2023, 74 : 293 - 306
  • [6] Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
    Diperi, Timothy P.
    Zhao, Ming
    Evans, Kurt W.
    Varadarajan, Kaushik
    Moss, Tyler
    Scott, Stephen
    Kahle, Michael P.
    Byrnes, Charnel C.
    Chen, Huiqin
    Lee, Sunyoung S.
    Halim, Abdel-Baset
    Hirai, Hiroshi
    Wacheck, Volker
    Kwong, Lawrence N.
    Rodon, Jordi
    Javle, Milind
    Meric-Bernstam, Funda
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : 322 - 334
  • [7] Detection of Known and Novel FGFR2 Geneomic Alterations in Intrahepatic Cholangiocarcinoma
    Pu, Xiaohong
    Fu, Yao
    Fan, Xiangshan
    Chen, Jun
    Sun, Beicheng
    LABORATORY INVESTIGATION, 2023, 103 (03) : S1405 - S1407
  • [8] Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression
    Morizane, Chigusa
    Ueno, Makoto
    Ioka, Tatsuya
    Tajika, Masahiro
    Ikeda, Masafumi
    Yamaguchi, Kensei
    Hara, Hiroki
    Yabusaki, Hiroshi
    Miyamoto, Atsushi
    Iwasa, Satoru
    Muto, Manabu
    Takashima, Tsutomu
    Minashi, Keiko
    Komatsu, Yoshito
    Nishina, Tomohiro
    Nakajima, Takako Eguchi
    Sahara, Takatoshi
    Funasaka, Setsuo
    Yashiro, Masakazu
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma
    Wu, Qibiao
    Zhen, Yuanli
    Shi, Lei
    Vu, Phuong
    Greninger, Patricia
    Adil, Ramzi
    Merritt, Joshua
    Egan, Regina
    Wu, Meng-Ju
    Yin, Xunqin
    Ferrone, Cristina R.
    Deshpande, Vikram
    Baiev, Islam
    Pinto, Christopher J.
    McLoughlin, Daniel E.
    Walmsley, Charlotte S.
    Stone, James R.
    Gordan, John D.
    Zhu, Andrew X.
    Juric, Dejan
    Goyal, Lipika
    Benes, Cyril H.
    Bardeesy, Nabeel
    CANCER DISCOVERY, 2022, 12 (05) : 1378 - 1395
  • [10] FGFR2 fusion in resectable intrahepatic cholangiocarcinoma patients
    Xu, S.
    Zheng, Y.
    Gong, W.
    Li, B.
    Wang, Y.
    Li, H.
    Zhao, S.
    Shi, X.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S267 - S267
12345